Invivyd reports sustained neutralization activity of PEMGARDA™ against dominant SARS-CoV-2 variants, supporting its ongoing emergency use status. Quiver AI Summary Invivyd, Inc. announced new in vitro ...
Invivyd, Inc. has announced new in vitro data showing that its monoclonal antibody PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the prevalent LP.8.1 variant of SARS-CoV-2, ...
A recent study published in Cell Reports demonstrated that vaccine-induced antibody functions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diminish with age. Study: BNT162b2 ...
According to more recent data, it has been determined that Pemgarda is likely to retain adequate neutralization activity against KP.3.1.1. The Food and Drug Administration (FDA) has updated the Fact ...
Epitope mapping was performed using structural analysis to classify antibodies according to their binding sites on the receptor-binding domain (RBD). The neutralization activity of representative ...
Booster doses of bivalent messenger RNA (mRNA) vaccines containing the ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the omicron B.1.1.529 (BA.4 and BA.5) variant spike ...
On Friday, Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda (pemivibart) and pipeline candidate VYD2311 against dominant SARS ...
A recent study posted in the Cell Reports Journal reported the identification of a panel of vaccinee-derived antibodies with broad-spectrum neutralization activity. Study: Potent, omicron-neutralizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results